Oncology Drugs - Czechia

Czechia

The revenue in the Oncology Drugs market in Czechia is forecasted to reach US$0.36bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 7.21%, leading to a market volume of US$0.51bn by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$103,900.00m in 2024.
The Czech Republic has seen a significant increase in the adoption of targeted therapy for cancer treatment in recent years.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in Czechia has been steadily growing in recent years, driven by several factors that are unique to the country.

Customer preferences: Czechia has a high incidence of cancer, which has led to an increased demand for oncology drugs. Patients in the country are also increasingly seeking out targeted therapies, which are becoming more widely available. Additionally, there is a growing preference for oral drugs over traditional intravenous treatments, as they offer greater convenience and ease of use.

Trends in the market: One trend in the Oncology Drugs market in Czechia is the increasing use of immunotherapy drugs, which stimulate the body's immune system to fight cancer cells. These drugs have shown promising results in treating various types of cancer and are becoming more widely available in the country. Another trend is the rise of biosimilars, which are cheaper versions of biologic drugs that have already been approved. These drugs are becoming more widely used in Czechia as they offer cost savings compared to the original drugs.

Local special circumstances: One factor that is unique to the Oncology Drugs market in Czechia is the country's healthcare system. The system is publicly funded, which means that patients have access to a range of treatments at no cost. However, the system is also underfunded, which has led to long wait times for certain treatments. This has led some patients to seek out private healthcare options, which can be expensive.

Underlying macroeconomic factors: The Czech economy has been growing steadily in recent years, which has led to increased investment in the healthcare sector. This has led to the development of new treatments and therapies, which are becoming more widely available in the country. Additionally, the country's membership in the European Union has led to greater regulatory harmonization, which has made it easier for companies to bring new drugs to market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.